tbuckley/cabot-search huggingface dataset:
MUCOUS COLITIS
Journal: JAMA (1920)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Thalidomide's back in the news, but in more favorable circumstances
Authors: T. Randall
Journal: JAMA (1990)

RESEARCHERS ARE taking a second look at what is perhaps the most notorious and stigmatized drug in the recent history of drug therapy: thalidomide. Once marketed as a sleeping pill, the drug is blamed for nearly 12 000 birth defects in the late 1950s, some 10 000 of these in the Federal Republic of (West) Germany alone. No other pharmaceutical has provoked such dramatic changes in the drug regulatory process around the world—a reputation that could have precluded its therapeutic use forever. But a series of chance events followed by an extensive body of research has uncovered a new side to the drug that its original manufacturers never imagined: thalidomide is a potent immunosuppressive that lacks the toxic side effects of steroids. This other side to thalidomide was discovered serendipitously by Israeli dermatologist J. Sheskin, MD, at Rothchild Hadassah University Hospital, Jerusalem, in 1965. He treated six of his lepromatous
ANTIHORMONES
Journal: JAMA (1934)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Epidemiology, diagnosis and management of hirsutism: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome Society
Authors: H.F. Escobar-Morreale, E. Carmina, D. Dewailly, A. Gambineri, F. Kelestimur, P. Moghetti, M. Pugeat, J. Qiao, C.N. Wijeyaratne, S.F. Witchel, R.J. Norman
Journal: Human Reproduction Update (2012)
EXPERIMENTAL STUDIES OF THE COMMON COLD
Journal: JAMA (1929)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Portal diversion. Treatment for glycogen storage disease and hyperlipemia
Authors: T. E. Starzl
Journal: JAMA (1975)

PORTAL vein diversion has been used for many years to stop or prevent hemorrhage from esophageal varices or, less commonly, to treat intractable ascites. Since both the bleeding and ascites formation are due, at least in part, to blockage of the splanchnic venous return at or near the liver, the objective has been purely hemodynamic: relieve the obstruction, and the resulting portal venous hypertension will also be relieved. Within the last few years, a new dimension has been added to the old operation of portacaval shunt by employing this procedure to favorably alter the course of patients with two inborn errors of metabolism, glycogen storage disease, and type II hyperlipoproteinemia. We will discuss the potential postoperative risks borne by patients submitted to portal diversion for these new indications and the probable mechanisms that explain the benefits of portacaval shunt—these have been clarified by some recent advances in hepatic physiology. <h3>Glycogen</h3>
Schroeder Instead of Schaefer.
Journal: JAMA (1931)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Lehrbuch DER SPEZIELLEN Pathologie UND THERAPIE DER inneren Krankheiten. Für studierende und Aerzte.
Journal: JAMA (1927)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Hepatology Highlights
Authors: Jinendra Satiya, Satinder P. Kaur, Daryl T.Y. Lau, Navid Hejazifar, Robert S. Brown, Jessica L. Maiers, Robert E. Schwartz, Adebowale O. Bamidele, Alyson Kaplan, Thuy‐Van P. Hang, Gopanandan Parthasarathy, Preeti A. Reshamwala, Nidhi Jalan‐Sakrikar, Enis Kostallari
Journal: Hepatology (2021)

Satiya, Jinendra*; Kaur, Satinder P.**; Lau, Daryl T.Y.1; Hejazifar, Navid***; Brown, Robert S. Jr.2; Maiers, Jessica L.3; Schwartz, Robert E.2; Bamidele, Adebowale O.3; Kaplan, Alyson***; Hang, Thuy‐Van P.****; Parthasarathy, Gopanandan3; Reshamwala, Preeti A.4; Jalan‐Sakrikar, Nidhi3; Kostallari, Enis3 Author Information
Carbamazepine‐induced thrombocytopenia defined by a challenge test
Authors: Takashi Ishikita, Akira Ishiguro, Kohji Fujisawa, Ichiro Tsukimoto, Toshikazu Shimbo
Journal: American Journal of Hematology (1999)

Carbamazepine (CBZ), a widely used anticonvulsant, occasionally causes serious hematologic disorders. A 12-year-old boy was admitted because of a diffuse petechial rash and profound thrombocytopenia (10 × 109 platelets/l), after having been treated for epilepsy with CBZ for 12 days. Seven days following withdrawal of CBZ and initiation of prednisolone therapy, the platelet count recovered. In a subsequent challenge test with CBZ, platelet counts again decreased, and the levels of platelet-associated IgG and serum interleukin-6 increased. No antibodies against platelet glycoprotein IIb/IIIa or Ib were detected in plasma. We believe that this is the first reported occasion when CBZ-induced thrombocytopenia has been defined by a rechallenge test. Am. J. Hematol. 64:52–55, 1999. © 1999 Wiley-Liss, Inc.
Abstract P4-03-08: Mechanisms of CD8+ T cell immunosuppression in triple negative breast cancer
Authors: T Gruosso, M Gigoux, N Bertos, D Zuo, V Manem, A Monette, R Lapointe, B Haibe-Kains, M Park
Journal: Cancer Research (2017)

Abstract Triple negative breast cancer (TNBC), defined as tumors lacking expression of the estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2), are especially difficult to treat effectively. While ER+ and HER2+ breast cancer subtypes can be treated with Tamoxifen and Herceptin, respectively, there are no targeted therapies for TNBC patients. Furthermore, while only 20-30% of TNBC patients respond to chemotherapy in the neoadjuvant setting, overall outcome remains poor for non-responding patients. However, mounting evidence suggests that immune-checkpoint inhibitor immunotherapies may be especially promising for TNBC patients. We and others have shown that the presence of CD8+ T cells, a crucial component of the cytotoxic arm of the adaptive immune response, is a sign of good clinical outcome in TNBC patients. However, good outcome only correlates with CD8 +T cell invasion of the tumor parenchyma. Some patients had an accumulation of CD8+ T cells in the surrounding tumor-associated stroma, but not the tumor epithelia, and these patients responded as poorly as patients with no CD8 T cells at all. Yet how cancer associated fibroblasts (CAFs), the dominant cell type of the tumor-associated stroma, affects CD8+ T cell invasion into the tumor epithelia is still poorly understood. To identify potential stroma-dependent mechanisms which potentiate or inhibit CD8+ T cells invasion into the tumor epithelia, we performed gene expression profiling of laser-capture microdissected tumor-associated stroma (and matched epithelia) from 38 TNBC cases. Here we identify several stromal and epithelial canonical pathways as well as biomarkers that are associated with and may explain the accumulation of CD8 T cells outside of the tumor epithelia. Citation Format: Gruosso T, Gigoux M, Bertos N, Zuo D, Manem V, Monette A, Lapointe R, Haibe-Kains B, Park M. Mechanisms of CD8+ T cell immunosuppression in triple negative breast cancer [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P4-03-08.
Phase II trial of combined temozolomide and pegylated liposomal doxorubicin in the treatment of patients with glioblastoma multiforme following concurrent radiotherapy and chemotherapy.
Authors: S. Ananda, A. K. Nowak, L. Cher, A. J. Dowling, C. Brown, R. J. Simes, M. Rosenthal
Journal: Journal of Clinical Oncology (2010)

2072 Background: Concurrent and post-radiotherapy temozolomide (TMZ) significantly improves survival in patients (pts) with newly diagnosed Glioblastoma Multiforme (GBM). Pegylated liposomal doxorubicin (D) has been evaluated in preclinical models and noted to penetrate the blood brain barrier. A phase I study confirmed that the combination of TMZ and D can be used safely at full doses. Phase II data supports efficacy of this combination in recurrent GBM. Methods: Eligible pts had histologically confirmed GBM, completed concurrent postoperative chemoradiotherapy (CRT) to 60Gy with TMZ (75 mg/m2 orally daily) according to the EORTC protocol, were considered suitable for further post CRT chemotherapy and had an ECOG PS 0-2. Post-CRT TMZ (initially 150 mg/m2 then increased to 200 mg/m2 orally, days 1-5) and D (40 mg/m2 intravenously day 1) were administered every 4 weeks for a maximum of 6 cycles. The primary endpoint was an improvement in 6 month progression-free survival (6-m PFS) measured from the date of registration on trial (after concurrent chemotherapy and irradiation), based on a Simon two stage approach with 40 pts as the planned total to be enrolled. Results: 40 eligible pts were enrolled: median age 53 years (range 24-76); ECOG PS status 0 (53%), 1 (40%), 2 (7%) and 73% were male. Six month PFS was 56% (95%CI 41-72%). PFS was comparable with pts in the EORTC study (personal communication R Stupp) matching these definitions. Median time to progression and overall survival (OS) were 6.1 months (95%CI 5.6-8.0 months) and 13.4 months (95%CI 10.2-17.3 months) respectively. Of 34 evaluable pts, one patient had a complete response (CR) (3%) and 28 had stable disease (SD) (70%). Treatment was well tolerated. There was one pt (3%) with grade 4 neutropenia. Three pts (8%) had grade 3 neutropenia and one grade 3 thrombocyotopenia was observed. Grade 3/4 non-hematologic toxicity included: palmar-plantar toxicity in 2 pts (5%) and a reaction to D in 1 patient (3%). Conclusions: The combination of TMZ and D is well tolerated, but based on the observed 6 PFS and OS, does not appear to add significant clinical benefit in the treatment of newly diagnosed GBM. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Schering-Plough Schering-Plough
Notch Signaling Is a Critical Regulator of Allogeneic T Cell Responses Mediating Graft-Versus-Host Disease.
Authors: Yi Zhang, Ashley R Sandy, Jina Wang, Koji Kato, Shan He, Ivy Tran, Gloria Tran Shan, Ann Friedman, Elizabeth Hexner, Stephen G. Emerson, Warren S. Pear, Ivan Maillard
Journal: Blood (2009)
Book reviews
Journal: Allergy (1989)

Books reviewed in this article: Mygind, N. &amp; Pipkorn, U. (eds.): Allergenic and vasomotor rhinitis: pathophysiological aspects. Croft, L. R. Allergy to bee stings and its prevention. Bibel, D. J. : Milestone in immunology. A historical exploration. Daróczy, J. : The dermal lymphatic capillaries. Iwanami, Y., Sasakuma, T. &amp; Yamada, Y. : Pollen: illustrations and scanning electronmicrographs. Podack, E. R.: (ed.) : Cytotoxic effector mechanisms. Current topics in microbiology and immunology. Cruse, J. M. &amp; Lewis, R. E.(eds.) : The year in immunology 1988. Immunoregulatory cytokines and cell growth. Dubos, R. J. &amp; Brock, T. D. : Pasteur and modern science.
BOOK REVIEWS
Authors: S. E. ETTINGHAUSEN
Journal: JNCI Journal of the National Cancer Institute (1992)

Journal Article BOOK REVIEWS Get access General Surgical Oncology Glenn Steele , Blake Cady , eds. Philadelphia : W. B. Saunders , 1992 . 366 pp., illus. $50. ISBN 0-7216-2471-5 STEPHEN E. ETTINGHAUSEN, M.D. STEPHEN E. ETTINGHAUSEN, M.D. Surgery Branch, Division of Cancer Treatment, National Cancer InstituteBldg. 10, Rm. 2B56, Bethesda, MD 20892 Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 84, Issue 21, 4 November 1992, Pages 1661–1662, https://doi.org/10.1093/jnci/84.21.1661-a Published: 04 November 1992
GALLOP RHYTHM
Authors: J V WARREN, J J LEONARD, A M WEISSLER
Journal: Annals of Internal Medicine (1958)

ExcerptTo many, gallop rhythm presents no problems. It is simply an extra heart sound in diastole heard in patients with actual or incipient congestive heart failure, and is of dire prognostic significance. Unfortunately, there is considerable evidence that the problem is not so simple. On careful study one finds similar diastolic heart sounds in normal persons. Gallop sounds are found in different parts of the diastolic phase, and the prognostic implications differ. With the current interest in more accurate cardiac diagnosis because of the increasing scope of cardiac surgery, the time would appear to be ripe for a reassessment of...
This Week in &lt;EMPH&gt;JAMA&lt;/EMPH&gt;
Journal: JAMA (2007)

A Piece of My Mind"All patients can be treated with respect and compassion-and thus be reassured that, at the very least, their physician cares about their welfare."From "The Importance of the Right Heart." SEE PAGE 447 Medical News & PerspectivesA growing body of evidence indicates that cognitive-behavioral therapy can be effective for children with some mental illnesses. SEE PAGE 453 HbA 1c Level as a Quality MeasureConsiderations and feasibility of hemoglobin A 1c (HbA 1c ) thresholds as a measure of diabetes care quality. SEE PAGE 520 Balancing PrioritiesReordering priorities in clinical practice, policy, and research to maximize health outcomes and control costs.
Book Review The Inner Ear, Including Otoneurology, Otosurgery, and Problems in Modern Warfare . By Joseph Fischer, M.D., and Louis E. Wolfson, M.D. 8°, cloth, 421 pp., with 77 illustrations and 7 tables. New York: Grune &amp; Stratton, 1943. $5.75.
Journal: New England Journal of Medicine (1944)
Effectiveness of Rollover Protective Structures for Preventing Injuries, Agricultural Tractors
Journal: JAMA (1993)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Exercise Testing
Authors: John L. Floyd
Journal: JAMA (1979)

<h3>To the Editor.—</h3> In the report by Hartley et al (241:269, 1979), a program of exercise testing was described that would be suited to serve large numbers of people economically. While much useful information may be gleaned from a properly performed stress ECG in selected patients, its use as a primary screening tool is subject to criticism. A screening test must have extreme sensitivity with acceptable specificity and be relatively inexpensive. While in a select group of subjects (patients who sought medical care because of chest pain) the specificity of the stress ECG is high (88% to 97%), its sensitivity is low (54% to 80%).<sup>1-5</sup>Thus, the predictive value of the test in a population with a low prevalence of "coronary disease-free" would be poor. It is therefore unlikely that the benefit to society of mass application of stress electrocardiography would parallel the reduction in cost of the procedure.
Letter: Phenytoin interference with dexamethasone
Authors: J. J. Boylan
Journal: JAMA (1976)

<h3>To the Editor.—</h3> Diphenylhydantoin, now officially named phenytoin, interferes with the effect of dexamethasone by increasing its renal and biliary excretion.<sup>1,2</sup>This acceleration of dexamethasone catabolism probably accounts for the failure of low doses of dexamethasone to suppress plasma corticosteroids and urinary 17-hydroxycorticosteroids when phenytoin is used concurrently.<sup>3</sup>The following report indicates that phenytoin may reduce the potency of dexamethasone in a patient with systemic lupus erythematosus (SLE). <h3>Report of a Case.—</h3> Systemic lupus erythematosus developed in a 15-year-old girl in 1973. It was manifested by arthritis, alopecia, leukopenia, fever, renal disease, and hypertension. Serum antinuclear antibody studies and lupus erythematosus preparations were positive. Serum C3 values ranged from 45 to 90 mg/100 ml. Urinary sediment contained numerous leukocytes, erythrocytes, and granular and red blood cell casts. Percutaneous renal biopsy revealed membranoproliferative glomerulonephritis. For 14 months, therapy was maintained with prednisone, methyldopa, chlorthalidone, and hydralazine hydrochloride. The patient
Skin tearing during corticosteroid therapy
Authors: James H. Penoff
Journal: JAMA (1980)

<h3>To the Editor.—</h3> Referring to the article by Gottlieb and Penneys, the ease of skin tearing in patients receiving long-term corticosteroid therapy has been well documented in the literature, and clinically I have seen a number of these cases. I would seriously doubt the spontaneous tearing of the skin as described in this particular article but would instead attribute this to extremely thin skin that responded to minimal trauma and therefore resulted in the defect. I doubt that the skin would split of its own accord, but certainly the minimal trauma of even brushing against a bed could cause this to occur. I have found the most effective method of treating this is to unfold all of the skin and steri-strip it. The skin that tears is usually extremely thin, almost having the appearance of wet tissue paper, but all the elements are there. This can be unfolded with a